Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ENGN 
enGene Holdings Inc. Common Stock (ENGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: ENGN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $23.5
1 Year Target Price $23.5
| 4 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 42.76% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 565.74M USD | Price to earnings Ratio - | 1Y Target Price 23.5 |
Price to earnings Ratio - | 1Y Target Price 23.5 | ||
Volume (30-day avg) 10 | Beta -0.27 | 52 Weeks Range 2.75 - 11.14 | Updated Date 12/14/2025 |
52 Weeks Range 2.75 - 11.14 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.9 |
Earnings Date
Report Date 2025-12-19 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.67% | Return on Equity (TTM) -43.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 395203674 | Price to Sales(TTM) - |
Enterprise Value 395203674 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.01 | Shares Outstanding 66872302 | Shares Floating 25046598 |
Shares Outstanding 66872302 | Shares Floating 25046598 | ||
Percent Insiders 0.26 | Percent Institutions 80.77 |
About enGene Holdings Inc. Common Stock
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2023-11-01 | President, CEO & Director Mr. Ronald H. W. Cooper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.engene.com |
Full time employees 56 | Website https://www.engene.com | ||
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.